Close Menu

NEW YORK – Invitae said this week that it completed its acquisition of Singular Bio on June 19. The deal was announced June 17. At closing, Invitae issued about 2.5 million shares of its common stock and approximately $5.7 million in cash to the former security holders of Singular Bio. Part of the cash consideration is being held back to satisfy potential indemnification obligations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.